{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Protéine M1 à motif en tête de fourche : Questions médicales les plus fréquentes",
"headline": "Protéine M1 à motif en tête de fourche : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Protéine M1 à motif en tête de fourche : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-08-05",
"dateModified": "2026-04-27",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Protéine M1 à motif en tête de fourche"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Facteurs de transcription Forkhead",
"url": "https://questionsmedicales.fr/mesh/D051858",
"about": {
"@type": "MedicalCondition",
"name": "Facteurs de transcription Forkhead",
"code": {
"@type": "MedicalCode",
"code": "D051858",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.930.977.249"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Protéine M1 à motif en tête de fourche",
"alternateName": "Forkhead Box Protein M1",
"code": {
"@type": "MedicalCode",
"code": "D000072278",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Meysam Moghbeli",
"url": "https://questionsmedicales.fr/author/Meysam%20Moghbeli",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: moghbelim@mums.ac.ir."
}
},
{
"@type": "Person",
"name": "I-Ching Wang",
"url": "https://questionsmedicales.fr/author/I-Ching%20Wang",
"affiliation": {
"@type": "Organization",
"name": "National Tsing Hua University, Taiwan."
}
},
{
"@type": "Person",
"name": "Vladimir V Kalinichenko",
"url": "https://questionsmedicales.fr/author/Vladimir%20V%20Kalinichenko",
"affiliation": {
"@type": "Organization",
"name": "Center for Lung Regenerative Medicine, Divisions of Pulmonary Biology and Developmental Biology, Cincinnati Children's Hospital Medical Center, College of Medicine of the University of Cincinnati, Cincinnati, Ohio."
}
},
{
"@type": "Person",
"name": "Iman Akhlaghipour",
"url": "https://questionsmedicales.fr/author/Iman%20Akhlaghipour",
"affiliation": {
"@type": "Organization",
"name": "Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran."
}
},
{
"@type": "Person",
"name": "Negin Taghehchian",
"url": "https://questionsmedicales.fr/author/Negin%20Taghehchian",
"affiliation": {
"@type": "Organization",
"name": "Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Comprehensive clinicopathological significance and putative transcriptional mechanisms of Forkhead box M1 factor in hepatocellular carcinoma.",
"datePublished": "2023-11-25",
"url": "https://questionsmedicales.fr/article/38001498",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12957-023-03250-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "[Retracted] Tetramethylpyrazine inhibits prostate cancer progression by downregulation of forkhead box M1.",
"datePublished": "2024-09-20",
"url": "https://questionsmedicales.fr/article/39301643",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3892/or.2024.8811"
}
},
{
"@type": "ScholarlyArticle",
"name": "Forkhead box M1 mediates metabolic reprogramming in human colorectal cancer cells.",
"datePublished": "2024-07-02",
"url": "https://questionsmedicales.fr/article/38953837",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1152/ajpgi.00032.2024"
}
},
{
"@type": "ScholarlyArticle",
"name": "Expression of Forkhead Box M1 (FOXM1) and anticancer effects of FOXM1 inhibition in epithelial sarcoma.",
"datePublished": "2024-06-08",
"url": "https://questionsmedicales.fr/article/38857782",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.labinv.2024.102093"
}
},
{
"@type": "ScholarlyArticle",
"name": "Rho GTPase activating protein 11A promotes tongue squamous cell carcinoma proliferation and is a transcriptional target of forkhead box M1.",
"datePublished": "2024-02-29",
"url": "https://questionsmedicales.fr/article/39347089",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jds.2024.02.015"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Facteurs de transcription",
"item": "https://questionsmedicales.fr/mesh/D014157"
},
{
"@type": "ListItem",
"position": 5,
"name": "Facteurs de transcription à motif hélice ailée",
"item": "https://questionsmedicales.fr/mesh/D051540"
},
{
"@type": "ListItem",
"position": 6,
"name": "Facteurs de transcription Forkhead",
"item": "https://questionsmedicales.fr/mesh/D051858"
},
{
"@type": "ListItem",
"position": 7,
"name": "Protéine M1 à motif en tête de fourche",
"item": "https://questionsmedicales.fr/mesh/D000072278"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Protéine M1 à motif en tête de fourche - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Protéine M1 à motif en tête de fourche",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-10",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Protéine M1 à motif en tête de fourche",
"description": "Comment diagnostiquer une dysrégulation de FOXM1 ?\nQuels marqueurs sont associés à FOXM1 ?\nFOXM1 est-il lié à des cancers spécifiques ?\nQuels tests sont utilisés pour évaluer FOXM1 ?\nFOXM1 peut-il être un indicateur de pronostic ?",
"url": "https://questionsmedicales.fr/mesh/D000072278#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Protéine M1 à motif en tête de fourche",
"description": "Quels symptômes sont liés à une surexpression de FOXM1 ?\nFOXM1 influence-t-il la progression tumorale ?\nY a-t-il des symptômes spécifiques au cancer du poumon ?\nLes symptômes de FOXM1 sont-ils visibles ?\nFOXM1 est-il associé à des symptômes neurologiques ?",
"url": "https://questionsmedicales.fr/mesh/D000072278#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Protéine M1 à motif en tête de fourche",
"description": "Peut-on prévenir la surexpression de FOXM1 ?\nY a-t-il des stratégies de dépistage pour FOXM1 ?\nL'alimentation influence-t-elle FOXM1 ?\nLe tabagisme affecte-t-il FOXM1 ?\nDes exercices physiques peuvent-ils aider ?",
"url": "https://questionsmedicales.fr/mesh/D000072278#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Protéine M1 à motif en tête de fourche",
"description": "Quels traitements ciblent FOXM1 ?\nFOXM1 peut-il être une cible pour l'immunothérapie ?\nComment la chimiothérapie affecte-t-elle FOXM1 ?\nY a-t-il des traitements combinés pour FOXM1 ?\nFOXM1 influence-t-il l'efficacité des traitements ?",
"url": "https://questionsmedicales.fr/mesh/D000072278#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Protéine M1 à motif en tête de fourche",
"description": "Quelles complications sont liées à FOXM1 ?\nFOXM1 est-il associé à des métastases ?\nLes complications varient-elles selon le type de cancer ?\nFOXM1 influence-t-il la survie des patients ?\nY a-t-il des complications neurologiques liées à FOXM1 ?",
"url": "https://questionsmedicales.fr/mesh/D000072278#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Protéine M1 à motif en tête de fourche",
"description": "Quels sont les facteurs de risque pour FOXM1 ?\nL'hérédité joue-t-elle un rôle dans FOXM1 ?\nLe stress influence-t-il FOXM1 ?\nL'alimentation peut-elle moduler FOXM1 ?\nY a-t-il des risques environnementaux associés à FOXM1 ?",
"url": "https://questionsmedicales.fr/mesh/D000072278#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysrégulation de FOXM1 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses d'expression génique peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels marqueurs sont associés à FOXM1 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les niveaux d'expression de FOXM1 peuvent être mesurés par PCR ou Western blot."
}
},
{
"@type": "Question",
"name": "FOXM1 est-il lié à des cancers spécifiques ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, FOXM1 est souvent surexprimé dans le cancer du sein et le cancer du poumon."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer FOXM1 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests d'immunohistochimie et les analyses transcriptomiques sont courants."
}
},
{
"@type": "Question",
"name": "FOXM1 peut-il être un indicateur de pronostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une forte expression de FOXM1 est souvent associée à un mauvais pronostic."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une surexpression de FOXM1 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes varient selon le cancer, mais peuvent inclure fatigue et perte de poids."
}
},
{
"@type": "Question",
"name": "FOXM1 influence-t-il la progression tumorale ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, FOXM1 favorise la prolifération cellulaire, contribuant à la progression tumorale."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques au cancer du poumon ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, toux persistante, essoufflement et douleurs thoraciques peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les symptômes de FOXM1 sont-ils visibles ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les symptômes sont souvent liés à des maladies sous-jacentes comme le cancer."
}
},
{
"@type": "Question",
"name": "FOXM1 est-il associé à des symptômes neurologiques ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études suggèrent un lien potentiel, mais des recherches supplémentaires sont nécessaires."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir la surexpression de FOXM1 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des choix de mode de vie sains peuvent réduire le risque de cancers associés à FOXM1."
}
},
{
"@type": "Question",
"name": "Y a-t-il des stratégies de dépistage pour FOXM1 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le dépistage précoce des cancers liés à FOXM1 peut aider à une détection rapide."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle FOXM1 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en antioxydants peut potentiellement moduler l'expression de FOXM1."
}
},
{
"@type": "Question",
"name": "Le tabagisme affecte-t-il FOXM1 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est un facteur de risque connu pour plusieurs cancers liés à FOXM1."
}
},
{
"@type": "Question",
"name": "Des exercices physiques peuvent-ils aider ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut réduire le risque de cancers associés à FOXM1."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent FOXM1 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs de FOXM1 et des thérapies géniques sont en cours d'étude."
}
},
{
"@type": "Question",
"name": "FOXM1 peut-il être une cible pour l'immunothérapie ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des approches immunothérapeutiques ciblant FOXM1 sont explorées."
}
},
{
"@type": "Question",
"name": "Comment la chimiothérapie affecte-t-elle FOXM1 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chimiothérapie peut réduire l'expression de FOXM1, affectant la résistance tumorale."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements combinés pour FOXM1 ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des traitements combinant chimiothérapie et inhibiteurs de FOXM1 sont étudiés."
}
},
{
"@type": "Question",
"name": "FOXM1 influence-t-il l'efficacité des traitements ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une forte expression de FOXM1 peut réduire l'efficacité des traitements anticancéreux."
}
},
{
"@type": "Question",
"name": "Quelles complications sont liées à FOXM1 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la progression rapide du cancer et la résistance au traitement."
}
},
{
"@type": "Question",
"name": "FOXM1 est-il associé à des métastases ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une forte expression de FOXM1 est souvent liée à des métastases dans divers cancers."
}
},
{
"@type": "Question",
"name": "Les complications varient-elles selon le type de cancer ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent différer selon le type de cancer et le stade de la maladie."
}
},
{
"@type": "Question",
"name": "FOXM1 influence-t-il la survie des patients ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une expression élevée de FOXM1 est souvent associée à une survie réduite des patients."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications neurologiques liées à FOXM1 ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études suggèrent un lien potentiel, mais des recherches supplémentaires sont nécessaires."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour FOXM1 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent le tabagisme, l'obésité et l'exposition à des agents cancérigènes."
}
},
{
"@type": "Question",
"name": "L'hérédité joue-t-elle un rôle dans FOXM1 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de cancer peuvent augmenter le risque de dysrégulation de FOXM1."
}
},
{
"@type": "Question",
"name": "Le stress influence-t-il FOXM1 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études suggèrent que le stress chronique peut affecter l'expression de FOXM1."
}
},
{
"@type": "Question",
"name": "L'alimentation peut-elle moduler FOXM1 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en graisses peut augmenter l'expression de FOXM1."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques environnementaux associés à FOXM1 ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des produits chimiques toxiques peut augmenter le risque de cancers liés à FOXM1."
}
}
]
}
]
}
Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: moghbelim@mums.ac.ir.
Publications dans "Protéine M1 à motif en tête de fourche" :
Center for Lung Regenerative Medicine, Divisions of Pulmonary Biology and Developmental Biology, Cincinnati Children's Hospital Medical Center, College of Medicine of the University of Cincinnati, Cincinnati, Ohio.
Publications dans "Protéine M1 à motif en tête de fourche" :
Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka 812-8582, Japan; Department of Pediatric Surgery, Faculty of Medicine, University of Tsukuba Hospital, Amakubo 2-1-1, Tsukuba, Ibaraki, 305-8576, Japan.
Publications dans "Protéine M1 à motif en tête de fourche" :
Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka 812-8582, Japan; Department of Pathology, Graduate School of Medicine, Osaka Metropolitan University, Asahimachi 1-4-3, Abeno-ku, Osaka 545-8585, Japan.
Publications dans "Protéine M1 à motif en tête de fourche" :
Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Shikata-cho 2-5-1, Kita-ku, Okayama 700-8558, Japan.
Publications dans "Protéine M1 à motif en tête de fourche" :
Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka 812-8582, Japan. Electronic address: oda.yoshinao.389@m.kyushu-u.ac.jp.
Publications dans "Protéine M1 à motif en tête de fourche" :
The Forkhead box M1 factor (FOXM1) is a crucial activator for cancer cell proliferation. While FOXM1 has been shown to promote hepatocellular carcinoma (HCC) progression, its transcriptional mechanism...
We performed an in-house tissue microarray on 313 HCC and 37 non-HCC tissue samples, followed by immunohistochemical staining. Gene chips and high throughput sequencing data were used to assess FOXM1 ...
This study, based on 4235 HCC tissue samples and 3461 non-HCC tissue samples, confirmed the upregulation of FOXM1 in HCC at mRNA and protein levels (standardized mean difference = 1.70 [1.42, 1.98]), ...
This study not only confirmed the upregulation of FOXM1 in HCC but also identified it as an independent risk factor. Moreover, our findings enriched our understanding of the complex transcriptional me...
Following the publication of this paper, it was drawn to the Editor's attention by a concerned reader that certain of the Transwell invasion assay data shown in Fig. 3B on p. 839 were strikingly simil...
Metabolic reprogramming is recognized as a hallmark of cancer, enabling cancer cells to acquire essential biomolecules for cell growth, often characterized by upregulated glycolysis and/or fatty acid ...
Epithelioid sarcoma (ES) is a rare aggressive sarcoma which, unlike most soft tissue sarcomas, shows a tendency toward local recurrence and lymph node metastasis. Novel antitumor agents are needed for...
Rho GTPase activating protein 11A (ARHGAP11A) can facilitate GTP hydrolysis in RhoA. The functions of ARHGAP11A in oral squamous cell carcinoma (OSCC) have not yet been explored. This study aimed to i...
Bioinformatics analysis was conducted using data from The Cancer Genome Atlas-Head and Neck Squamous Cell Carcinoma (TCGA-HNSC). Lentiviruses carrying...
This study revealed the oncogenic role of ARHGAP11A in TSCC, highlighting its impact on cell-cycle control and tumor proliferation. Furthermore, the regulatory relationship between FOXM1 and ARHGAP11A...
Insect pathogenic fungi have shown great potential in agricultural pest control. Conidiation is crucial for the survival of filamentous fungi, and dispersal occurs through two methods: normal conidiat...
Cisplatin (CDDP) is one of the most common chemotherapy drugs used in a wide range of cancer patients; however, there is a high rate of CDDP resistance among cancer patients. Considering the side effe...
Stem cells are pivotal players in the intricate dance of embryonic development, tissue maintenance, and regeneration. Their behavior is delicately balanced between maintaining their pluripotency and d...
Liver regeneration is vital for the recovery of liver function after injury, yet the underlying mechanism remains to be elucidated. Forkhead box protein A3 (FOXA3), a member of the forkhead box family...
Here, we explored whether Foxa3 regulates liver regeneration via acute and chronic liver injury mice models. We further characterised the molecular mechanism by chromatin immunoprecipitation sequencin...
Foxa3 is dominantly expressed in hepatocytes and cholangiocytes and is induced upon partial hepatectomy (PH) or carbon tetrachloride (CCl...
These data characterise Foxa3 as a vital regulator of liver regeneration, which may represent an essential factor to maintain liver mass after liver injury by governing Cebpb transcription....
Liver regeneration is vital for the recovery of liver function after chemical insults or hepatectomy, yet the underlying mechanism remains to be elucidated. Herein, via...
Breast cancer, a prominent cause of mortality among women, develops from abnormal growth of breast tissue, thereby rendering it one of the most commonly detected cancers in the female population. Alth...